Talcum Powder / Johnson & Johnson Baby Powder Litigation

Johnson & Johnson's iconic Baby Powder — one of the most recognized consumer products in American history — has become the subject of the largest and most consequential active mass tort in the United States. Approximately 67,100 lawsuits allege the product was contaminated with asbestos, a known human carcinogen, and that decades of use for feminine hygiene purposes caused ovarian cancer and mesothelioma.

Talc (hydrous magnesium silicate) is a naturally occurring mineral frequently mined in geological proximity to asbestos deposits, creating an inherent contamination risk in talc mining and processing. J&J sourced its talc from mines across the globe, including operations in Vermont, Italy, China, and India.

The litigation gained explosive momentum in 2018 when a Reuters investigation, based on internal J&J documents spanning decades, reported that the company's own testing had detected asbestos fibers in its talc supply as early as the 1970s. Internal memos suggested company executives, scientists, and lawyers were aware of contamination concerns but chose not to disclose them publicly. Some documents showed J&J scientists recommending that testing methods be modified to avoid detecting asbestos.

J&J discontinued talc-based Baby Powder in North America in May 2020, replacing it with a cornstarch-based formula. The company continued selling talc-based products internationally until 2023. J&J maintains that its talc products were safe and asbestos-free, characterizing the litigation as driven by unreliable testing methodologies and opportunistic litigation.

In a controversial legal maneuver that has become a landmark in bankruptcy law, J&J employed the 'Texas Two-Step' bankruptcy strategy three times. The company created a subsidiary called LTL Management LLC, transferred all talc liabilities to it, and then placed that subsidiary in Chapter 11 bankruptcy — effectively attempting to cap the company's total liability. Federal courts rejected this approach all three times, with the Third Circuit finding the first filing was not in good faith, the second filing similarly rejected, and a federal judge rejecting the third attempt ($9 billion settlement offer) on March 31, 2025, on procedural and voting grounds. The MDL is now proceeding toward trial.

The question of whether talc itself — independent of asbestos contamination — causes ovarian cancer has been studied for over four decades, making it one of the most extensively researched product liability causation questions in history.

The epidemiological evidence is substantial. A meta-analysis published in the journal Epidemiology found a statistically significant 30-60% increase in ovarian cancer risk among women who used talc for genital hygiene. Multiple additional cohort and case-control studies have replicated this finding. The proposed biological mechanism involves talc particles migrating through the reproductive tract — from the external genitalia through the vagina, uterus, and fallopian tubes — to the ovarian epithelium, where they cause chronic inflammation that can lead to malignant transformation.

The International Agency for Research on Cancer (IARC), a specialized agency of the World Health Organization, classifies genital use of talc-based body powder as 'possibly carcinogenic to humans' (Group 2B). This classification is based on 'limited evidence' of carcinogenicity in humans and 'inadequate evidence' in experimental animals.

Regarding asbestos contamination specifically, independent laboratory testing commissioned by the FDA and other entities has detected asbestos fibers — including chrysotile, tremolite, and anthophyllite — in certain J&J talc product samples. Asbestos is classified as a known human carcinogen (Group 1 by IARC) and is an established cause of mesothelioma. Internal J&J documents obtained in litigation show the company's own labs detected asbestos contamination in some talc samples dating back to the early 1970s.

The FDA conducted its own testing of talc-based cosmetic products between 2018 and 2020 and detected asbestos in some samples of J&J Baby Powder purchased from retail stores. J&J disputed these findings, citing different testing methodologies.

Areas of scientific debate remain. Some epidemiologists argue that the association between genital talc use and ovarian cancer, while statistically significant, is modest in magnitude and could be influenced by recall bias (women with cancer are more likely to remember past talc use). J&J's expert witnesses have emphasized this uncertainty. However, multiple juries have found the plaintiffs' scientific evidence persuasive.

Women who used Johnson & Johnson Baby Powder or other talc-based body powders for feminine hygiene (genital or perineal dusting) over extended periods — typically years to decades — and were subsequently diagnosed with ovarian cancer, fallopian tube cancer, or peritoneal cancer may be affected.

Additionally, any individuals with prolonged occupational or personal talc exposure who developed mesothelioma — regardless of gender — may have claims. Occupational exposure includes talc miners, processors, and workers in industries using talc as an ingredient.

The affected population spans generations, as Baby Powder was marketed as a daily hygiene staple for over a century. Statutes of limitations generally run 2-3 years from diagnosis or discovery of the connection to talc, though this varies significantly by state.

This eligibility information is general and informational only. Whether you have a viable legal claim depends on the specific facts of your situation and the laws of your jurisdiction. Consult a licensed attorney.

As of March 2026, approximately 67,100 talc lawsuits remain pending in MDL No. 2738 and state courts, making it the largest active mass tort MDL in the United States.

J&J's third attempt to use the 'Texas Two-Step' bankruptcy strategy to cap liability at $9 billion was rejected by a federal judge on March 31, 2025, on procedural and voting grounds. The company had required 75% claimant approval for the bankruptcy plan but failed to achieve that threshold amid opposition from many plaintiff attorneys representing tens of thousands of claimants who argued the offer undervalued their clients' claims.

With the bankruptcy maneuver definitively off the table, the MDL is now proceeding toward federal bellwether trials. Discovery has produced significant internal documents, and trial preparation is accelerating.

Recent trial results demonstrate the magnitude of jury exposure: a February 2026 Baltimore jury awarded $1.56 billion against J&J. A March 2026 Philadelphia jury found J&J liable for a woman's fatal ovarian cancer. A separate $950 million punitive damages award was vacated by a judge who found insufficient evidence of malice in that specific case. These verdicts underscore the substantial per-case exposure J&J faces if the MDL proceeds to trial without a global settlement.

A federal court also barred the law firm Beasley Allen from the talc litigation's leadership committee after finding improper collaboration with a former J&J attorney, adding procedural complexity to the MDL.

Johnson & Johnson has maintained throughout the litigation that its talc-based Baby Powder products were safe, pure, and free of asbestos contamination. The company argues that the scientific evidence linking genital talc use to ovarian cancer is unreliable, citing the modest magnitude of the statistical association and the potential for recall bias in epidemiological studies. J&J's expert witnesses have contested both the general causation (whether talc causes ovarian cancer) and specific causation (whether talc caused cancer in individual plaintiffs).

Regarding asbestos contamination, J&J argues that its own comprehensive testing over decades confirmed the absence of asbestos, and that positive asbestos findings by other laboratories resulted from unreliable testing methodologies or contamination during sample handling. The company has pointed to its voluntary discontinuation of talc-based Baby Powder in North America as a business decision driven by declining consumer confidence rather than safety concerns.

J&J's three attempts to use the Texas Two-Step bankruptcy strategy reflect the company's position that the litigation has spiraled beyond rational case valuation. The company argued that its $9 billion settlement offer was generous and fair, and that the bankruptcy process would ensure equitable distribution among all claimants. Critics have characterized the bankruptcy strategy as an abuse of the legal system designed to shield a solvent, profitable corporation from jury accountability.

Kenvue Inc., the consumer health company spun off from J&J in 2023, has inherited certain talc-related liabilities. J&J and Kenvue have established indemnification agreements governing responsibility for talc claims.

J&J's proposed $9 billion settlement — structured through the third LTL Management bankruptcy filing — was rejected on March 31, 2025. This was the company's third failed attempt to achieve a global resolution through bankruptcy.

Prior to the bankruptcy maneuvers, J&J settled approximately 1,000 individual cases privately. Settlement amounts in these early resolutions have not been publicly disclosed but reportedly varied significantly based on the nature of injury (ovarian cancer versus mesothelioma) and the strength of evidence.

Individual trial verdicts have been extraordinary and establish the upper range of potential case values: a 2018 St. Louis jury awarded $4.69 billion to 22 women (later reduced to $2.12 billion on appeal); a February 2026 Baltimore jury awarded $1.56 billion; and multiple other trials have produced nine- and ten-figure verdicts. The total litigation exposure has been estimated by financial analysts at potentially tens of billions of dollars.

With no global settlement in place, the litigation appears headed for bellwether trials in the MDL, which could result in additional large verdicts and increase pressure for a comprehensive resolution.

Past settlement amounts are not a guarantee of future results. Individual claim values vary significantly based on diagnosis, exposure history, and case-specific evidence.